New hope for rare bone cancer? drug shows promise in early trial
NCT ID NCT01267955
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested vismodegib, a pill that targets a specific growth pathway, in 45 people with advanced chondrosarcoma (a rare bone cancer). The goal was to see if the drug could shrink tumors or stop them from growing. Participants had to have measurable disease and no more than three prior chemotherapy treatments. The study used a two-stage design to decide if the drug was worth further study.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Vismodegib (a targeted cancer drug taken by mouth)
What this could lead to
If it works, this could provide a new treatment option for people with advanced chondrosarcoma, a rare bone cancer that currently has few effective therapies.
What could go wrong
This is a small, early-phase trial with only 45 participants, so results may not apply to everyone. The drug may not shrink tumors or improve survival, and side effects like muscle spasms, hair loss, and fatigue are common.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEDIFFERENTIATED CHONDROSARCOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Centre Leon Berard
Lyon, 69373, France
-
Centre Oscar Lambert
Lille, 59020, France
-
Gustave Roussy
Villejuif, 94805, France
-
Hopital De La Timone
Marseille, 13385, France
-
Institut Bergonie Cancer Center
Bordeaux, 33076, France
-
Institut Curie Paris
Paris, 75005, France